UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

December 22, 2022

R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.

November 03, 2022

Uproleselan, an agent that disrupts the interaction between leukemia cells and their protective E-selectin microenvironment, is a promising novel AML therapy that may increase the efficacy and durability of other AML treatments.

November 01, 2022

Center will serve as a hub for commercialization of promising cancer therapies.

October 24, 2022

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

October 16, 2022

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

September 06, 2022

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

July 25, 2022

UC Davis cancer researchers hope new technology will help diagnose and treat melanoma more successfully.

July 13, 2022

R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.

April 15, 2022

For patients with osteosarcoma or Ewing sarcoma who develop pathologic fractures, the prognosis remains poor; however, there is still the possibility for limb salvage therapy.

March 28, 2022

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

January 26, 2022

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

January 06, 2022

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

December 20, 2021

The Board of Directors of the International Association for the Study of Lung Cancer is pleased to announce the appointment of Karen L. Kelly, M.D. to the position of Chief Executive Officer, effective Spring 2022.

December 16, 2021

R. Lor Randall, MD, FACS, elaborates on the results of a study and provided insight into future research directions in Ewing sarcoma

December 10, 2021

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

November 18, 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

October 26, 2021

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

October 25, 2021

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

October 07, 2021

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

October 06, 2021

Pivotal trials, such as the phase 3 FLAURA trial with osimertinib in patients with EGFR-mutant non–small cell lung cancer NSCLC, have demonstrated the significant benefit yielded with targeted therapies.